ensidipine generic drug

Ensidipine (enasidenib) is an inhibitor of isocitrate dehydrogenase2 indicated for the treatment of isocitrate dehydrogenase2 detected in an FDA-approved test (IDH2)Adult patients with relapsed or refractory acute myeloid leukemia(AML). The therapeutic effect is remarkable.

The currently officially marketed versions of ensidipine include the Bangladeshi version and the Lao version. Currently, Bangladesh’s Ziska Pharmaceuticals and Bangladesh’s Everest Pharmaceuticals are producing generic ensidipine drugs, and Laos’ Lucius Pharmaceuticals is producing them. Ensidipine50mg 60tablets produced by Ziska Pharmaceuticals4about one thousand, ensidipine50mg30tablets produced by Everest Pharmaceuticals pan>5about one thousand, Laos Lucius Pharmaceuticals50mg30 capsules2around one thousand, patients can choose the drug version according to their own economic situation.

The usual adult dose for acute myeloid leukemia is 100 mg PO once daily with or without food, Duration of treatment is Treat until disease progression or unacceptable toxicity, For patients without disease progression or unacceptable toxicity, Treat for at least 6 months to allow for time for clinical response. If you take the missed dose on the same day, take the next dose at your normal time and stick to the once-daily schedule and do not use 2 doses in one day. Other drugs may affectensidipine, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all the medicines you currently take and any medicines you start or stop taking. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.